The vaccine Pfizer BioNTech is 73.2% effective in preventing Covid-19 Among children aged 6 months to 4 years, new data from the companies this Tuesday (23) show that two months after the start of the vaccine’s application USA For that age group.
The Pfizer-BioNTech vaccine was approved in June for children under 5 in the US, based on data showing the vaccine produces an immune response similar to that of adults.
A preliminary analysis based on ten symptomatic Covid-19 cases in the study suggested a vaccine efficacy of 80.3%. Experts cautioned that the data is preliminary because of the small number of symptomatic cases.
Updated data released Tuesday showed that 13 children developed Covid-19 at least seven days after receiving the third dose of the Pfizer-BioNTech vaccine, compared with 21 cases among those who received the placebo.
Pfizer and BioNTech said they are preparing a US approval application for a so-called bivalent vaccine targeting Omicron’s BA.4/BA.5 subvariants for children under 12 years of age.
The companies applied Monday for US approval of the bivalent vaccine as a booster in people 12 years and older.
Musicaholic. Twitter guru. Total bacon fanatic. Zombie ninja. Freelance student. Coffee fan. Gamer.